Back to search results

ActiGraft Treatment for Cutaneous Wounds

This observational study is looking at how well ActiGraft, a whole blood clot (WBC) gel, works in treating skin wounds that are oozing (exuding cutaneous wounds) in everyday medical settings. The study aims to enroll about 500 adults aged 18 and older who have these types of wounds. To join, you must agree to share your health data, including wound photos, and be able to read and understand English or Spanish. Researchers will measure how much your wound area shrinks after 4 weeks and will also track any side effects over 1 year. The study's current status is unclear.

Study design
This is an observational study, meaning researchers will watch how ActiGraft is used in real life. It plans to include about 500 participants.
What's involved
You would agree to the use of your health data, including photos of your wound, for analysis and publications.
Compensation
Not stated in the trial record.
Follow-up
Your wound area will be measured at 4 weeks, and any side effects will be tracked for 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04699305

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

Recruiting
Not specifiedAges 18+Observational
RedDress Ltd.
~500 participants
Updated 2025-07-29 on ClinicalTrials.gov
What's tested:ActiGraft

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage area reduction (PAR) at 4 weeks
Measured over 4 weeks
+1 more outcome measured

Conditions

Cutaneous Wounds

Explore related trials

Diabetic foot ulcerPressure SoreSurgical woundTrauma WoundVascular WoundWound of skin

Where it's being run

1 sites across 1 states
Nevada1

Study leadership

  • Sharon Sirota · STUDY_DIRECTOR · RedDress Ltd.

Who to contact

Sharon Sirota
[email protected]
+972545800765
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject is ≥18 years of age
Subject has an exuding cutaneous wound
Subject agrees to the use of his health data, including photos of his wound in analysis and publications
Subject/LAR must be able to read and understand English and/or Spanish

Exclusion

Subject/LAR is unable to read and understand English or Spanish.

What this trial measures

  • Percentage area reduction (PAR) at 4 weeks4 weeks

    Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).

  • Nature, frequency, and severity of adverse events in the intent to treat population1 year

    Nature, frequency, and severity (by CTCAE5) of adverse events